--- title: "Trump wants to loosen regulations, cannabis stocks soar collectively" type: "News" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/269527601.md" description: "Trump plans to reclassify marijuana as a \"lower-risk drug,\" driving significant increases in related stocks. Stocks of companies such as Tilray Brands, Canopy Growth, and Aurora Cannabis surged in pre-market trading in the U.S. Trump has discussed this matter with several officials and executives in the cannabis industry, but no final decision has been made yet. Reclassification could reduce criminal consequences and lift certain federal tax restrictions" datetime: "2025-12-12T13:18:03.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/269527601.md) - [en](https://longbridge.com/en/news/269527601.md) - [zh-HK](https://longbridge.com/zh-HK/news/269527601.md) --- > 支持的语言: [English](https://longbridge.com/en/news/269527601.md) | [繁體中文](https://longbridge.com/zh-HK/news/269527601.md) # Trump wants to loosen regulations, cannabis stocks soar collectively According to reports from multiple local media outlets in the United States, President Donald Trump is expected to push for the reclassification of cannabis as a "lower-risk drug." This latest market development has undoubtedly driven the stocks of U.S. cannabis producers to surge significantly in pre-market trading on Friday. Leading the gains are: Tilray Brands (TLRY.US) up over 30% in pre-market, Canopy Growth (CGC.US) up 23%, Aurora Cannabis (ACB.US) up 20%, SNDL (SNDL.US) up 14%, and Cronos Group (CRON.US) up 12%. Media reports indicate that Trump is considering a significant adjustment of cannabis from "Schedule I"—a category indicating no medical use and high potential for abuse—to "Schedule III"—a category for substances with lower potential for dependence and addiction. Reportedly, Trump spoke earlier on Thursday with House Speaker Mike Johnson, Robert F. Kennedy Jr., whom Trump personally nominated as Secretary of Health and Human Services (HHS), Mehmet Oz, Director of the Centers for Medicare & Medicaid Services (CMS), and several executives from the cannabis industry to discuss the matter. However, a senior White House official indicated that Trump has not yet made a final administrative decision. Schedule III drugs have accepted medical uses but still carry a risk of slight abuse and potential physical or psychological dependence. Examples include ketamine, anabolic steroids, and Tylenol with codeine. Schedule I drugs primarily include LSD and heroin. In March 2024, the Department of Justice under the Biden administration proposed to reclassify cannabis to Schedule III. However, the Drug Enforcement Administration (DEA) first rescheduled the hearing and then completely canceled the hearings on the matter. During the 2024 U.S. presidential campaign, Trump publicly promised to "unlock the medical uses of cannabis and reclassify it as a Schedule III drug." The reclassification would not only reduce the criminal consequences for personal use but also eliminate certain federal tax and business barriers (such as allowing domestic cannabis businesses to deduct commercial expenses), improving the operating environment for the industry and benefiting businesses and practitioners supporting the legal cannabis industry. Before being officially nominated by Trump in 2024 as Secretary of Health and Human Services, Kennedy had repeatedly called for an end to the criminalization of cannabis and the implementation of a regulated legal sales system, a view seen as relatively open among some reformists and industry supporters. During his Senate confirmation hearing, Kennedy stated that HHS would "listen to and review the scientific data regarding the reclassification of cannabis" and would make judgments based on existing reviews by professional agencies like the DEA, rather than proactively proposing significant legislative or administrative relaxations ### 相关股票 - [Aurora Cannabis (ACB.US)](https://longbridge.com/zh-CN/quote/ACB.US.md) - [Tilray Brands (TLRY.US)](https://longbridge.com/zh-CN/quote/TLRY.US.md) ## 相关资讯与研究 - [Ahead of Q3 Earnings, What Do Analysts Think About TLRY Stock?](https://longbridge.com/zh-CN/news/281184635.md) - [Tilray stock couldn’t sustain its Trump gains. How cannabis earnings could help.](https://longbridge.com/zh-CN/news/272109971.md) - [We’re on the cusp of something this country has never seen, Trump said. Here’s how to gear up for the golden age of America](https://longbridge.com/zh-CN/news/281680416.md) - [Vireo Growth Closes Eaze Deal, Expands Cannabis Footprint to 10 States](https://longbridge.com/zh-CN/news/281418680.md) - [Trump: I think we'll make a deal with them pretty soon…](https://longbridge.com/zh-CN/news/280929294.md)